This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Mirvaso® approved by European Commission
Galderma has announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso is an alpha-2 adrenergic receptor agonist that acts rapidly and can